Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 16/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27082923 | 0.81 | MAPKAPK2 (0.33) | MAPKAPK2ALDH1A1 | |
| SCHEMBL30835271 | 0.81 | MAPKAPK2 (0.33) | MAPKAPK2ALDH1A1 | |
| SCHEMBL12791498 | 0.78 | MAPK1 (0.31) | ALDH1A1 | |
| SCHEMBL23214000 | 0.75 | MAPKAPK2 (0.34) | MAPKAPK2ALDH1A1RECQLKDM4ENOTUM | |
| SCHEMBL20189316 | 0.75 | MAPKAPK2 (0.51) | MAPKAPK2 | |
| SCHEMBL23214613 | 0.75 | ALDH1A1 (0.39) | MAPKAPK2ALDH1A1KDM4E | |
| SCHEMBL31134680 | 0.75 | MAPKAPK2 (0.51) | MAPKAPK2 | |
| SCHEMBL30529535 | 0.74 | PDXK (0.35) | MAPKAPK2ALDH1A1RECQLKDM4ENOTUM | |
| SCHEMBL19641414 | 0.74 | PDXK (0.35) | MAPKAPK2ALDH1A1RECQLKDM4ENOTUM | |
| SCHEMBL30121642 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3548033-B1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116763791-A | Compounds and methods of use thereof | 普拉克西斯精密药物股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-110337295-B | Compounds and methods of use thereof | 普拉克西斯精密药物股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | SCN1A, SCN5A, SCN3A | MAPKAPK2 1779/4885ALDH1A1 1589/4885RECQL 3331/4885 |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | MAPKAPK2 3210/4885ALDH1A1 916/4885RECQL 2080/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | MAPKAPK2 3210/4885ALDH1A1 916/4885RECQL 2080/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | MAPKAPK2 3210/4885ALDH1A1 916/4885RECQL 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.